3 Cash-Flow Machines Investors May Want Heading Into 2026 [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Gilead is pushing long-acting HIV treatments based on lenacapavir—testing two paths (lenacapavir plus bNAbs infusions and lenacapavir plus the long-acting integrase GS-3242)—with pharmacokinetics supporting current four-month dosing and an objective of once-every-six-months regimens. For HIV prevention, the company is developing a 12-month lenacapavir PrEP using a higher-dose intramuscular formulation and an FDA-agreed model-based PK study, targeting a 2027 data readout and potential 2028 availability. Outside HIV, Gilead aims to expand liver-disease use of Livdelzi (the IDEAL phase III could roughly double the PBC addressable population ) while accelerating oncology via the Arcellx acquisition for anito-cel, broad Trodelvy pivotal programs, and long-term bets on in-vivo CAR-T. Interested in Gilead Sciences, Inc.? Here are five stocks we like better. 3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) executives outlined the company's approach to ne
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast CancerPR Web
- Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades [Yahoo! Finance]Yahoo! Finance
- Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]Yahoo! Finance
- Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/16/26 - Form 144
- GILD's page on the SEC website